BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) — Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders, today announced the closing of its initial public offering of 9,200,000 shares of its common stock at a public offering price of $17.00 per share, which includes 1,200,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. Rapport’s shares began trading on the Nasdaq Global Market on June 7, 2024, under the ticker symbol “RAPP.” All of the shares of common stock were sold by Rapport.
Goldman Sachs & Co. LLC, Jefferies, TD Cowen and Stifel acted as joint book-running managers for the offering.
In addition to the shares sold in the initial public offering, Rapport today announced the closing on June 10, 2024, of its sale of 1,058,824 shares of common stock at the public offering price per share in a concurrent private placement to certain of its existing stockholders. The …
Full story available on Benzinga.com
BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) — Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders, today announced the closing of its initial public offering of 9,200,000 shares of its common stock at a public offering price of $17.00 per share, which includes 1,200,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. Rapport’s shares began trading on the Nasdaq Global Market on June 7, 2024, under the ticker symbol “RAPP.” All of the shares of common stock were sold by Rapport.
Goldman Sachs & Co. LLC, Jefferies, TD Cowen and Stifel acted as joint book-running managers for the offering.
In addition to the shares sold in the initial public offering, Rapport today announced the closing on June 10, 2024, of its sale of 1,058,824 shares of common stock at the public offering price per share in a concurrent private placement to certain of its existing stockholders. The …
Full story available on Benzinga.com
BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) — Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders, today announced the closing of its initial public offering of 9,200,000 shares of its common stock at a public offering price of $17.00 per share, which includes 1,200,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. Rapport’s shares began trading on the Nasdaq Global Market on June 7, 2024, under the ticker symbol “RAPP.” All of the shares of common stock were sold by Rapport.
Goldman Sachs & Co. LLC, Jefferies, TD Cowen and Stifel acted as joint book-running managers for the offering.
In addition to the shares sold in the initial public offering, Rapport today announced the closing on June 10, 2024, of its sale of 1,058,824 shares of common stock at the public offering price per share in a concurrent private placement to certain of its existing stockholders. The …Full story available on Benzinga.com Read MoreNews, RAPP, IPOs, Press Releases IPOs
